PD-1 and its ligands in tolerance and immunity.

By M. Keir, M. Butte, G. Freeman, Arlene H. Sharpe. Annual Review of Immunology, 2008

5,308 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Challenges in liver cancer and possible treatment approaches (2019, background): “Designing mAbs against the immune checkpoint regulator, PD-1, reduces T-cell apoptosis, potentiates antitumor immunity, and inhibits cell proliferation [74, 75].”
Overcoming T cell exhaustion in infection and cancer (2015, background): “Studies in preclinical models have greatly contributed to our understanding of the PD-1 pathway in the regulation of T cell immunity [3, 37, 96].”
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition (2016, background): “In addition, T cell activation increases the expression of PD-1 on the T cell itself (3).”
The Pathogenesis of Sepsis (2011, background): “PD-L2 is more restricted and is inducible only on dendritic cells, macrophages, bone marrow–derived mast cells, and specific peritoneal B cells (31, 32).”